LipoScience (FRA:LI0) EPS (Basic) : €-0.64 (TTM As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is LipoScience EPS (Basic)?

LipoScience's basic earnings per share (Basic EPS) for the three months ended in Sep. 2014 was €-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.64.

LipoScience's EPS (Diluted) for the three months ended in Sep. 2014 was €-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.64.

LipoScience's EPS without NRI for the three months ended in Sep. 2014 was €-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2014 was -0.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

LipoScience EPS (Basic) Historical Data

The historical data trend for LipoScience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LipoScience EPS (Basic) Chart

LipoScience Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

EPS (Basic)

0.29

-0.52

0.11

-0.62

LipoScience Quarterly Data
	Mar11	Jun11	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
EPS (Basic)	Get a 7-Day Free Trial								-0.23	-0.13	-0.09	-0.20	-0.22

LipoScience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

LipoScience's Basic EPS for the fiscal year that ended in Dec. 2013 is calculated as

Basic EPS (A: Dec. 2013 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-9.151	-	0)	/	14.820
	=	-0.62

LipoScience's Basic EPS for the quarter that ended in Sep. 2014 is calculated as

Basic EPS (Q: Sep. 2014 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.306	-	0)	/	15.283
	=	-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64

LipoScience (FRA:LI0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

LipoScience EPS (Basic) Related Terms

Thank you for viewing the detailed overview of LipoScience's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

LipoScience (FRA:LI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LipoScience Inc (FRA:LI0) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.liposcience.com

LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.

LipoScience (FRA:LI0) Headlines

No Headlines